Please wait

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Name of Issuer)

(Title of Class of Securities)

(CUSIP Number)

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13D/A 0000950170-24-139724 0001878692 XXXXXXXX LIVE 4 Common stock, par value $0.0001 per share 03/04/2025 false 0001422142 00032Q104 Aadi Bioscience, Inc. 17383 Sunset Boulevard Suite A250 Pacific Palisades CA 90272 Neil Desai (424) 744-8055 17383 Sunset Boulevard Suite A250 Pacific Palisades CA 90272 0001878692 N Neil Desai PF N X1 461700 1811241 461700 2272941 2272941 N 4.9 IN (1) Consists of 461,700 shares of Common Stock issuable upon exercise of options exercisable within 60 days of March 4, 2025, subject to Dr. Desai's continued service through each vesting date. (2) Consists of 639,698 shares of Common Stock directly owned by the Anishka Irrevocable 2016 Trust dated October 19, 2016 (the "Anishka Irrevocable Trust") and 1,171,543 shares of Common Stock directly owned by Neil Prafulla Desai, Trustee of the Anishka Family Trust (the "Anishka Family Trust"). Dr. Desai and his spouse share voting and dispositive power over the shares held by the Anishka Irrevocable Trust and the Anishka Family Trust and each of Dr. Desai and his spouse is a trustee of the Anishka Irrevocable Trust and the Anishka Family Trust. (3) Based on the quotient obtained by dividing (a) the aggregate number of shares of Common Stock beneficially owned by Dr. Desai by (b) the sum of (i) 46,294,912 shares of Common Stock outstanding as of March 4, 2025, based on information provided to Dr. Desai by the Issuer, and (ii) 461,700 shares of Common Stock issuable upon exercise of options exercisable within 60 days of March 4, 2025 held by Dr. Desai. The aggregate number of shares of Common Stock beneficially owned by Dr. Desai as set forth in clauses "(a)" and "(b)" of this footnote are treated as outstanding shares of Common Stock only for the purpose of computing the percentage ownership of Dr. Desai. Common stock, par value $0.0001 per share Aadi Bioscience, Inc. 17383 Sunset Boulevard Suite A250 Pacific Palisades CA 90272 This Amendment No. 4 ("Amendment No. 4") amends the Statement of Beneficial Ownership on Schedule 13D, filed with the Securities and Exchange Commission (the "Commission") by Neil Desai on September 8, 2021 (the "Schedule 13D"), which was previously amended by Amendment No. 1, as filed with the Commission on January 17, 2023, Amendment No. 2, as filed with the Commission on October 1, 2024, and Amendment No. 3, as filed with the Commission on December 23, 2024, with respect to the shares of Common Stock of the Issuer. Except as specifically provided herein, this Amendment No. 4 does not modify any of the information previously reported in the Schedule 13D, which remains unchanged. On March 4, 2025, the Issuer issued and sold 21,592,000 shares of the Issuer's common stock in a private placement "PIPE Financing," which was previously disclosed on December 19, 2024 and approved by the Issuer's stockholders at a special meeting on February 28, 2025. As a result, Dr. Desai ceased to be the beneficial owner of more than five percent of the shares of Common Stock of the Issuer. Neil Desai /s/ Neil Desai Neil Desai 03/06/2025